The therapeutic potential of TNF-α antagonists for skin psoriasis comorbidities

Expert Opinion on Biological Therapy

Volumn 10, Issue 8, 2010, Pages 1197-1208

  Piérard, Gérald E ^a   Piérard Franchimont, Claudine ^a   Szepetiuk, Grégory ^a   Paquet, Philippe ^a   Quatresooz, Pascale ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adalimumab; Biological; Cardiovascular disease; Crohn's disease; Metabolic syndrome; Psoriasis; Psoriatic arthropathy; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; ISONIAZID; METHOTREXATE; PLACEBO; PSORALEN; RETINOID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D DERIVATIVE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; BACTERIAL ARTHRITIS; BODY MASS; BONE EROSION; BRONCHITIS; CANCER GROWTH; CARDIOVASCULAR DISEASE; CELLULITIS; CHEST TIGHTNESS; CLINICAL TRIAL; COMORBIDITY; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DIVERTICULITIS; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG MECHANISM; DYSPNEA; ENTERITIS; ENTHESOPATHY; ERYSIPELAS; FACE EDEMA; GRANULOMA; GRANULOMA ANNULARE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LATENT TUBERCULOSIS; LEUKOPENIA; LIP DISEASE; LIP EDEMA; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOMA; METABOLIC SYNDROME X; MORTALITY; NEPHROTOXICITY; PARADOXICAL PSORIASIS; PATHOPHYSIOLOGY; PROSTHESIS INFECTION; PRURITUS; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ALOPECIA; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUVA; PYELONEPHRITIS; RECOMMENDED DRUG DOSE; REVIEW; SARCOIDOSIS; SIDE EFFECT; SKIN INFLAMMATION; SURGICAL INFECTION; TH1 CELL; TH17 CELL; THROMBOCYTOPENIA; TONGUE EDEMA; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VASCULITIS; WEIGHT GAIN; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; IMMUNOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; COMORBIDITY; CROHN DISEASE; HUMANS; METABOLIC SYNDROME X; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77954665047     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.500283     Document Type: Review

References (166)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-1912
2. Guttman-Yassky E, Krueger JG. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007;157:1103-1115
3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-873
4. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-271
5. Uhoda I, Pierard GE, Pierard-Franchimont C, et al. Vascularity and fractal dimensions of the dermo-epidermal interface in guttate and plaque type psoriasis. Dermatology 2005;210:189-193
6. Sabat R, Philipp S, Hoflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007;16:779-798
7. Charles J, Chaperot L, Salameire D, et al. Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. Eur J Dermatol 2010;20:16-23
8. Philipp S, Wolk K, Kreutzer S, et al. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin Ther Targets 2006;10:817-831
9. Leon A, Nguyen A, Letsinger J, et al. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic option. Expert Opin Pharmacother 2007;8:617-632
10. Vanden Eijnden S, Goriely S, De Wit D, et al. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol 2005;35:469-475
11. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23, IL-17 immune pathway. Trends Immunol 2006;27:17-23
12. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-949
13. Liu H, Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 2008;180:7948-7957
14. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28:454-467
15. Steinman L. A rush to judgment on Th17. J Exp Med 2008;205:1517-1522
16. Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009;29:210-214
17. Arican O, Aral M, Sasmz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005:273-279
18. Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007;25:568-573
19. Banno T, Gazel A, Bumenberg M. Effects of tumor necrosis factor-alpha (TNF-alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004;279:32633-32642
20. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumor necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20
21. Kawaguchi M, Mitsuhashi Y, Kondo S. Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis. Br J Dermatol 2005;152:915-919
22. Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-beta1. Expert Rev Dermatol 2007;2:69-78
23. Pierard-Franchimont C, Henry F, Szepetiuk G, Pierard GE. Psoriasis comorbidities and anti-TNFalpha therapy using adalimumab (Humira® ). Rev Med Liege (In Press)
24. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007;25:529-534
25. Gladman DD, Farewell VT, Husted J, et al. Mortality studies in psoriatic arthritis. Results from a single centre. II. Prognostic indicators for mortality. Arthritis Rheum 1998;41:1103-1110
26. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-1499
27. Stenn K, Paus R. Controls of hair follicle cycling. Physiol Rev 2001;81:449-494
28. Pierard-Franchimont C, Pierard GE. Teloptosis, a turning point in hair shedding biorhythms. Dermatology 2001;230:115-117
29. Courtois M, Loussouarn G, Hourseau C, et al. Hair cycle and alopecia. Skin Pharmacol 1994;7:84-89
30. Pierard-Franchimont C, Petit L, Loussouarn G, et al. The hair eclipse phenomenon: sharpening the focus on the hair cycle chronobiology. Int J Cosmet Sci 2003;25:295-299
31. Pierard GE, Pierard-Franchimont C, Marks R, et al. EEMCO guidance for the assessment of hair shedding and alopecia. Skin Pharmacol Physiol 2004;17:98-110
32. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64:14-17
33. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005;64:ii3-ii8
34. Gottlieb AB, Mease PJ, Mark Jackson J, et al. Clinical characteristics ofpsoriatic arthritis and psoriasis in dermatologists' office. J Dermatol Treat 2006;17:279-287
35. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Dermatol Venereol 2002;82:108-113
36. Gisondi P, Girolomoni G, Sampogna F, et al. Prevalence of psoriatic arthritis and joints complaints in a large population of Italian patients hospitalized for psoriasis. Eur J Dermatol 2005;15:279-283
37. Radtke MA, Reich K, Blome C, et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results ofa German national survey. J Eur Acad Dermatol Venereol 2009;23:683-691
38. Kana D, Stafford L, Bresniham B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003;42:1460-1468
39. Duffin KC, Wong B, Horn EJ, et al. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol 2009;60:604-608
40. Abu-Amer Y, Erdmann J, Alexopoulou L, et al. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000;275:27307-27310
41. Mensah KA, Schwarz EM, Ritchlin CT. Altered bone remodeling in psoriatic arthritis. Curr Rheumatol Rep 2008;10:311-317
42. Ozcakar L, Cetin A, Inanici F, et al. Ultrasonographical evaluation of the Achilles' tendon in psoriasis patients. Int J Dermatol 2005;44:930-932
43. Gisondi P, Tinazzi I El-Dalati G, et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis 2008;67:26-30
44. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's diseases. J Am Acad Dermatol 2003;48:805-821
45. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006;298:309-319
46. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009;23:561-565
47. Torres MI, Rios A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol 2008;14:1972-1980
48. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide associated study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-1463
49. Grundy SM, Cleeman JL, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association / National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752
50. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480
51. You T, Yang R, Lyles MF, et al. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005;288:E741-7
52. Nickoloft BJ, Nestle FO. Recent insights into the immunopathogenesis ofpsoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-1675
53. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006;29:81-90
54. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-1534
55. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73
56. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-572
57. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741
58. Neimann AL, Shin DB, Wang W, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-835
59. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol 2007;57:347-354
60. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 2009;218:110-113
61. Duprez DA, Cohn JN. Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep 2007;9:139-144
62. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-276
63. Neimann AL, Shin DB, Wang X, et al. Prevalence ofcardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-835 (Pubitemid 44556851)
64. Saphiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007;56:629-634
65. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008;217:27-37
66. Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009;219:209-218
67. Pathirana D, Omerod AD, Saiag P, et al. European S3-guindelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:S1-70
68. Paquet P, Pierard GE. Breast and lung cancers in two cyclosporine A-treated psoriatic women. Dermatology 1998;196:450-452
69. Schafer I, Hacker J, Rustenbach SJ, et al. Concordance of the psoriasis area and severity index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010;20:62-67
70. Weinberg JM. An overview of infliximab, etanercept, efalizumab and alefacept as biologic therapy for psoriasis. Clin Ther 2003;25:2487-2505
71. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004;63:769-773
72. Koo J, Khera P. Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci 2005;38:75-87
73. Smith CH, Antstey AV, Barker JN, et al. British association of dermatologists. British association of dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-497
74. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33:1447-1451
75. Nickoloff BJ, Bonish BK, Marble DJ, et al. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling and inflammation. J Investig Dermatol Symp Proc 2006;11:16-29
76. Van de KerkhofPC. Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Dermatol Venereol 2006;20:639-650
77. Vena GA, Cassano N. Anti-tumor necrosis factor therapies for psoriasis. Expert Rev Dermatol 2007;2:335-349
78. Pastore S, Gubinelli E, Leoni L, et al. Biological drugs targeting the immune response in the therapy ofpsoriasis. Biologics 2008;2:687-697
79. Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment ofpsoriasis. J Drugs Dermatol 2009;8:546-559
80. Mossner R, Reich K. Management of severe psoriasis with TNF antagonists. Adalimumab, etaercept and infliximab. Curr Probl Dermatol 2009;38:107-136
81. Pierard-Franchimont C, Quatresooz P, Paquet P, et al. A range oftargeted treatments using monoclonal antibodies in dermatology. Current and future practice. Rev Med Liege 2009;64:334-338
82. Saccomani C, Penz S, Guerre-Schmidt R, et al. Biological therapy for psoriasis: practical experiences at a French dermatology unit. Ann Dermatol Venereol 2009;136:877-882
83. Sobell JM, Kalb RE, Weinberg JM. Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents. J Drugs Dermatol 2009;8:147-154
84. Griffiths CEM, Strober BE, van de KerkhofP, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-128
85. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-2729
86. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-230
87. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update ofprevious guidelines of April 2001). Rheumatology 2005;44:157-163
88. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol 2006;54:S85-91
89. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-1430
90. Gonzalez-Juanatey C, Llorca J, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:287-293 (Pubitemid 47164092)
91. Huvers FC, Popa C, Netera MG, et al. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 2007;66:558-559
92. Ludwig RJ Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development ofcoronary artery calcification. Br J Dermatol 2007;156:271-276
93. Saraceno R, Schipani C, Mazzota A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008;57:290-295
94. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 2009;3:77-97
95. Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009;22:61-73
96. Marchesoni A, Altomare G, Matucci-Cerinic M, et al. An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease. J Eur Acad Dermatol Venereol 2010;24:578-586
97. Garcia Bartels N, Lee HH, Worm M, et al. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 2006;142:1654-1655
98. Chaves Y, Duarte G, Ben-Said B, et al. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 2008;217:380
99. Pelivani N, Hassan AS, Braathen LR, et al. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 2008;216:320-323
100. Kirshen C, Kanigsberg N. Alopecia areata following adalimumab. J Cutan Med Surg 2009;13:48-50
101. El Shabrawi-Caelen L, La Placa M, Vincenzi C, et al. Adalimumab-induced psoriasis ofthe scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis 2010;16:182-183
102. Mease PJ. Psoriatic arthritis update. Bull NYU Hosp Jt Dis 2006;64:25-31
103. Ali Y, Tom BDM, Schentag CT, et al. Improved survival in psoriatic arthritis (PsA) with calendar time. Arthritis Rheum 2007;56:2708-2714
104. Mease PJ, Signorovitch J, Yu AP, et al. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials. Dermatology 2010;220:1-7
105. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowen diseases. Biologics 2009;3:77-97
106. Leso V, Leggio L, Armuzzi A, et al. Role ofthe tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol 2010;22:779-786
107. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumour necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008;57:290-295
108. Gisondi P, Cotena C, Tessari G, et al. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008;22:341-344
109. Bonilla E, Lee YY, Phillips PE, et al. Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis 2007;66:1688
110. Boulton JG, Bourne JT. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis. Rheumatology 2007;46:178-179
111. Wu JJ, Tsai TF. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol 2008;144:1403-1404
112. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008;75:22-24
113. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-572
114. Irace C, Mancuso G, Fiaschi E, et al. Effect of anti-TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004;177:113-118
115. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-1218
116. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004;51:447-450
117. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003;107:3133-3140
118. Viguier M, Richette P, Bachelez H, et al. Paradoxical cutaneous manifestations during anti-TNF-alpha therapy. Ann Dermatol Venereol 2010;137:64-71
119. Richette P, Viguier M, Bachelez H, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect? J Rheumatol 2007;34:438-439
120. Eriksen KW, Lovato P, Skov L, et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 2005;125:936-944
121. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-143
122. Shear NH. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 2006;29:49-66
123. Goiriz R, Dauden E, Perez-Gala S, et al. Flare and change ofpsoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol 2007;32:176-179
124. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001
125. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008;22:341-344
126. Wu JJ, Tsai TF. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol 2008;144:1403-1404
127. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment ofpsoriasis: what do we really know? Dermatol Ther 2009;22:431-440
128. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2009;20:100-108
129. Pierard-Franchimont C, Pierard GE. Cutaneous adverse reactions to monoclonal antibody treatments. Rev Med Liege 2009;64:339-346
130. Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNFalpha treatment: onset or exacerbation ofcutaneous disorders. Exp Rev Clin Immunol 2009;5:421-431
131. Dutz JP. Tumor necrosis factor-alpha inhibition and palmoplantar pustulosis: Janus-faced therapy? J Rheumatol 2007;34:247-249
132. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007;34:380-385
133. De Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-231
134. Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010;62:430-440
135. Borras-Blasco J, Gracia-Perez A, Nunez-Cornejo C, et al. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther 2008;33:321-325
136. Sari I, Akar S, Birlik M, et al. Anti-tumor necrosis factor-alpha-induced psoriasis. J Rheumatol 2006;33:1411-1414
137. Wendling D, Balblanc JC, Brianon D, et al. Onset of exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 2008;75:315-318
138. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006:73:710-713
139. Wendling D, Streit G, Lehuede G, et al. Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis. Joint Bone Spine 2006;73:215-216
140. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 33 cases. Medicine 2007;86:242-251
141. Ramos-Casals M, Brito-Zeron P, Cuadrado MJ, et al. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Res 2008;10:442-448
142. Massara A, Cavazzini L, La Corte R, et al. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 2009;39:313-319
143. Voulgari PV, Markatseli TE, Exarchou SA, et al. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:567-570
144. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 2006;142:198-202
145. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-3194
146. Revicki DA, Willan MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate-to-severe plaque psoriasis. J Dermatol Treat 2007;18:341-350
147. Nijsten T, Spuls PL. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis. Br J Dermatol 2008;159:257-258
148. Ryan C, Kirby B, Collins P, Rogers S. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol 2009;34:784-788
149. Schmitt J, Wozel G. Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics 2009;3:303-318
150. Turner D, Picot J, Cooper K, Loveman E. Adalimumab for the treatment of psoriasis. Health Technol Assess 2009;13:S49-54
151. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Vener 2009;23(Suppl 2):S1-S70
152. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606
153. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-115
154. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-566
155. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 2005;l52:3279-3289
156. Simpson D, Scott LJ. Adalimumab in psoriatic arthritis. Drugs 2006;66:1487-1496
157. Gladman DD, Mease PJ, Cifaldi MA, et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the adalimumab effectiveness in psoriatic arthritis trial. Ann Rheum Dis 2007;66:163-168
158. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis 2009;68:702-709
159. Mease PJ, Signorovitch J, Yu AP, et al. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis. A pooled analysis of randomized clinical trials. Dermatology 2009;220:1-7
160. Mueller RB, Ogilvie A, Schwarz S, et al. Adalimumab treatment of a patient with psoriasis suppurativa hallopeau associated osteoarthropathy. Clin Exp Rheum 2009;27:887
161. Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis skin and nail lesions. Ann Rheum Dis 2009;69:394-399
162. Shramm C, Schneider A, Marx A, Lohse AW. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol 2008;46:1369-1371
163. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:758-764
164. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:778-786
165. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British society for rheumatology biologics register. Ann Rheum Dis 2009;68:209-215
166. Lacana E, Amur S, Mummanneni P, et al. The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther 2007;82:466-471